Patents by Inventor James Gillard
James Gillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969353Abstract: The present disclosure relates to prosthesis systems having trays and liners having an asymmetrical locking mechanism to bias the strength of the liner to resist loading forces and associated methods. The tray has a lateral groove disposed in an inner surface of a lateral circumferential portion of the tray and a medial groove disposed in an inner surface of a medial circumferential portion of the tray. The liner has an upper segment and a lower segment. The liner has a locking portion for lockingly engaging the tray that includes the lower segment. The locking portion has a lateral toe positioned generally diametrically opposite a plurality of resiliently deformable medial fingers defined therein. The liner and the tray are engageable in a lateral-to-medial direction so that the plurality of medial fingers can resiliently deform to engage the medial groove subsequent to engagement of the lateral toe within the lateral groove.Type: GrantFiled: June 3, 2020Date of Patent: April 30, 2024Assignee: Zimmer, Inc.Inventors: Steven Humphrey, James D. Wernle, Joanna Surma, Stephen H. Hoag, Donald W. Dye, Kenton A. Walz, Terry W. Wagner, Kathleen Macke, Duane Gillard, Brian D. Byrd, Ken Yamaguchi
-
Publication number: 20210300932Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.Type: ApplicationFiled: March 26, 2021Publication date: September 30, 2021Inventors: Manuel Perez VAZQUEZ, M. Monzur MORSHED, Jennifer L. HICKEY, Adam Paul KAFAL, James GILLARD, Narendra PATEL, Sai Kumar CHAKKA, Andrew L. ROUGHTON, Marc-André POUPART, Gaoqiang YANG
-
Patent number: 11072616Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.Type: GrantFiled: November 14, 2016Date of Patent: July 27, 2021Assignees: Universite de Montreal, Zealand Pharma A/SInventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
-
Patent number: 11046695Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: GrantFiled: November 14, 2016Date of Patent: June 29, 2021Assignees: Zealand Pharma A/S, Universite de MontrealInventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
-
Patent number: 10981921Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: GrantFiled: August 4, 2020Date of Patent: April 20, 2021Assignee: Zealand Pharma A/SInventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
-
Publication number: 20200361944Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Inventors: Manuel Perez VAZQUEZ, M. Monzur MORSHED, Jennifer L. HICKEY, Marc-André POUPART, Gaoqiang YANG, James GILLARD, Adam Paul KAFAL, Andrew L. ROUGHTON
-
Publication number: 20200165300Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.Type: ApplicationFiled: November 14, 2016Publication date: May 28, 2020Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
-
Publication number: 20190077805Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: ApplicationFiled: November 14, 2016Publication date: March 14, 2019Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
-
Patent number: 9334249Abstract: Compounds of Formula (I) wherein n, R1, R1A, R2, R4 and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: GrantFiled: October 31, 2013Date of Patent: May 10, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Lee Fader, Mathieu Parisien, Carl Thibeault, Louis Morency, Martin Duplessis, Clint James, Sébastien Morin, James Gillard
-
Publication number: 20150284348Abstract: Compounds of Formula (I) wherein n, R1, R1A, R2, R4 and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: ApplicationFiled: October 31, 2013Publication date: October 8, 2015Inventors: Lee Fader, Mathieu Parisien, Carl Thibeault, Louis Morency, Martin Duplessis, Clint James, Sébastien Morin, James Gillard
-
Publication number: 20120101091Abstract: The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other antiviral agent in the treatment of a hepatitis C viral infection in a mammal having or at risk of having the infection.Type: ApplicationFiled: October 1, 2009Publication date: April 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre Beaulieu, Pierre Bonneau, René Coulombe, Pasquale Forgione, James Gillard, Araz Jakalian, Jean Rancourt
-
Patent number: 7893084Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of whichType: GrantFiled: November 26, 2008Date of Patent: February 22, 2011Assignee: Boehringer Ingelheim Canada Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, Eric Jolicoeur, James Gillard, Marc-André Poupart, Jean Rancourt
-
Patent number: 7803944Abstract: An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; — represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5 wherein R5 has the same definition as R4 defined above; M is N or CR7, wherein R7 has the same definition as R4 defined above; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.Type: GrantFiled: August 15, 2006Date of Patent: September 28, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Pierre Louis Beaulieu, Gulrez Fazal, George Kukolj, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Patent number: 7576079Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; ?represents either a single or a double bond; R2 is selected from 6 or 10-membered aryl and Het, each optionally substituted with R20; provided that Het is not a 5- or 6-membered monocyclic heterocycle having 1 or 2 nitrogen heteroatoms; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-arylType: GrantFiled: January 17, 2006Date of Patent: August 18, 2009Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, James Gillard, Marc-Andre Poupart
-
Publication number: 20090087409Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, alType: ApplicationFiled: November 26, 2008Publication date: April 2, 2009Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Patent number: 7439258Abstract: A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl,Type: GrantFiled: May 21, 2004Date of Patent: October 21, 2008Assignee: Boehringer Ingelheim (Canada) LtdInventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
-
Publication number: 20080132496Abstract: Substituted carboxylic acid amides of general formula wherein A, B, and R1 to R5 are as defined herein, and the tautomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, such as antithrombotic activity and factor Xa-inhibiting activity.Type: ApplicationFiled: November 30, 2007Publication date: June 5, 2008Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: James Gillard, Sandra Ruth Handschuh, Herbert Nar, Roland Pfau, Henning Priepke, Wolfgang Wienen, Annette Mario Schuler-Metz, Eckhart Bauer, Georg Dahmann, Kai Gerlach
-
Patent number: 7326791Abstract: Substituted carboxylic acid amides of general formula wherein A, B, and R1 to R5 are as defined herein, and the tautomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, such as antithrombotic activity and factor Xa-inhibiting activity.Type: GrantFiled: December 19, 2003Date of Patent: February 5, 2008Assignee: Boehringer Ingelheim Pharma GmbH & Co., KGInventors: James Gillard, Sandra Ruth Handschuh, Herbert Nar, Roland Pfau, Henning Priepke, Wolfgang Wienen, Annette Mario Schuler-Metz, Eckhart Bauer, Georg Dahmann, Kai Gerlach
-
Patent number: 7157486Abstract: An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; ----- represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4 defined above; M is N or CR7, wherein R7 has the same definition as R4 defined above; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.Type: GrantFiled: July 18, 2002Date of Patent: January 2, 2007Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, George Kukolj, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20060293306Abstract: An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; — represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5 wherein R5 has the same definition as R4 defined above; M is N or CR7, wherein R7 has the same definition as R4 defined above; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.Type: ApplicationFiled: August 15, 2006Publication date: December 28, 2006Inventors: Pierre Beaulieu, Gulrez Fazal, George Kukolj, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt